Similar articles

• Regulation of cytosolic guanylyl cyclase by nitric oxide: the NO-cyclic GMP signal transduction system.

  Murad F. Murad F. Adv Pharmacol. 1994;26:19-33. doi: 10.1016/s1054-3589(08)60049-6. Adv Pharmacol. 1994. PMID: 7913616 Review.
• Inhibition of nitric oxide-guanylate cyclase-dependent and -independent signaling contributes to impairment of beta-adrenergic vasorelaxations by cyclosporine.

  El-Mas MM, Sharabi FM, El-Gowilly SM, El-Din MM. El-Mas MM, et al. Biochem Pharmacol. 2007 Feb 1;73(3):359-67. doi: 10.1016/j.bcp.2006.10.015. Epub 2006 Oct 21. Biochem Pharmacol. 2007. PMID: 17113040
• Blockade of nitric oxide-evoked smooth muscle contractions by an inhibitor of guanylyl cyclase.

  Olgart C, Wiklund NP, Gustafsson LE. Olgart C, et al. Neuroreport. 1997 Oct 20;8(15):3355-8. doi: 10.1097/00001756-199710200-00032. Neuroreport. 1997. PMID: 9351671
• cGMP signalling beyond nitric oxide.

  Mayer B, Koesling D. Mayer B, et al. Trends Pharmacol Sci. 2001 Nov;22(11):546-8. doi: 10.1016/s0165-6147(00)01889-7. Trends Pharmacol Sci. 2001. PMID: 11698077 No abstract available.
• [Function of soluble guanylate cyclase and nitric oxide].

  Makino R. Makino R. Tanpakushitsu Kakusan Koso. 1997 Feb;42(3 Suppl):379-84. Tanpakushitsu Kakusan Koso. 1997. PMID: 9162974 Review. Japanese. No abstract available.